Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors

项目摘要/摘要：该项目将把两种皮肤VOC传感器(手持、可穿戴)带入临床 用于改进对一系列健康状况的快速诊断。皮肤VOC监测是一个新概念， 改变医疗保健的潜力。我们的假设是微型皮肤挥发性有机化合物分析设备可以耦合 使用生命体征传感器实时测量疾病特征，速度比传统的鉴别诊断更快。 这项提议有四个目标：(1)将我们目前的挥发性有机化合物(VOC)检测器改装成手持式检测器 与非侵入性生命体征传感器和人造血管连接的气相皮肤散发代谢物的格式 智能机器学习(AI/ML)算法；(2)在20种疾病上部署我们的手持皮肤VOC系统 超过5年；(3)调整我们目前的可穿戴式生命监测系统，以包括我们的皮肤VOC检测器，并使用 这是为了监测持续性哮喘患者的疾病闪光；(4)为我们的项目和设备移动做准备 通过商业化制造、标准化和FDA监管批准。为了实现这些目标，我们 计划如下：在目标1中，我们将我们的微型VOC检测设备用于皮肤测量，并将 它配有7个商业现成的生命体征传感器(皮温、脉搏、呼吸频率、心率、 血氧饱和度、皮肤电反应、皮肤湿度)。我们的微型差示迁移率光谱仪 检测器与芯片预浓缩器和微型化学气相色谱柱相耦合 分离和检测。已经开发出了单独的组件。在MPI教授的指导下。 加州大学戴维斯分校机械和航空航天工程主席戴维斯，一个工程师团队将对这些部件进行改造 一起放入用于皮肤VOC采样/分析的手持式单元中。联席教授蔡教授将指导 AI/ML功能，用于从集成的VOC和生命体征数据进行自动数据处理和解释 溪流。在Aim#2中，我们将在两个不同的临床站点使用这个手持系统来开发AI/ML签名 对20种不同的疾病与适当选择的对照组进行比较。加州大学戴维斯分校由MPI Nicholas领导的网站 凯尼恩将专注于：2种皮肤病(湿疹、牛皮癣)，7种肺部疾病(哮喘、慢性阻塞性肺疾病) 肺部疾病，肺纤维化，肺高压，肺栓塞，结节病，镰状细胞 有呼吸道症状的疾病)、3种关节和结缔组织疾病(类风湿性关节炎、牛皮癣 关节炎、骨关节炎)、4种精神健康疾病(注意力缺陷多动障碍、自闭症、精神分裂症、 具有心理健康症状的脆性X先兆突变)。由Co-I牵头的费城儿童医院网站 奥黛丽·约翰将专注于：4种儿科发烧(尿路感染、肠道病毒感染、呼吸道合胞病毒感染 病毒感染、流感感染)。在Aim#3中，我们的团队将结合我们目前可穿戴的生命体征传感器 使用我们的微型VOC传感器，并从两个样本中识别出持续哮喘疾病爆发的新特征 数据流。目标4将开发制造、商业化、标准化和FDA监管 我们的设备/测试的路径。这些努力是与加州大学戴维斯分校的初创公司SensIT Ventures合作的。

Project Summary/Abstract: This project will bring two skin VOC sensors (hand-held, wearable) into clinical use to improve rapid diagnostics for a range of health conditions. Skin VOC monitoring is a new concept with potential to transform healthcare. Our hypothesis is that miniature skin VOC analysis devices can be coupled with vital sign sensors to measure disease signatures in real-time faster than a traditional differential diagnosis. The proposal has four goals: (1) adapt our current volatile organic compound (VOC) detector into a hand-held format for gas phase skin-emitted metabolites, coupled to non-invasive vital sign sensors and artificial intelligence machine learning (AI/ML) algorithms; (2) deploy our hand-held skin VOC system on 20 diseases over 5 years; (3) adapt our current wearable vital monitoring system to include our skin VOC detector, and use this to monitor persistent asthma patients for disease flares; (4) prepare for our project and devices to move through commercial manufacturing, standardization and FDA regulatory approval. To meet these goals, we plan the following: in Aim #1, we adapt our miniature VOC detection device for skin measurements, and couple it with 7 commercial-off-the-shelf vital sign sensors (skin temperature, pulse rate, respiration rate, heart rate, oxygen saturation, galvanic skin response, skin humidity). Our miniature differential mobility spectrometry detector is coupled with a chip-based preconcentrator and miniature gas chromatograph column for chemical separation and detection. Individual components have already been developed. Under direction of MPI Prof. Davis, UC Davis Chair of Mechanical and Aerospace Engineering, a team of engineers will adapt these pieces together into a hand-held unit for skin VOC sampling/analysis. Co-I Prof. Chuah will guide development of AI/ML capability for automated data processing and interpretation from the integrated VOC and vital sign data streams. In Aim #2, we will use this hand-held system at two different clinical sites to develop AI/ML signatures for 20 different diseases compared to appropriately selected controls. The UC Davis site led by MPI Nicholas Kenyon will focus on: 2 skin diseases (eczema, psoriasis), 7 lung diseases (asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pulmonary embolism, sarcoidosis, sickle cell disease with respiratory symptoms), 3 joint and connective tissue diseases (rheumatoid arthritis, psoriatic arthritis, osteoarthritis), 4 mental health diseases (attention deficit hyperactivity disorder, autism, schizophrenia, Fragile X premutation with mental health symptoms). The Children’s Hospital of Philadelphia site lead by Co-I Audrey John will focus on: 4 pediatric fevers (urinary tract infection, enterovirus infection, respiratory syncytial virus infection, influenza infection). In Aim #3, our team will combine our current wearable vital sign sensors with our miniature VOC sensor, and identifying a novel profile for persistent asthma disease flares from both data streams. Aim #4 will develop a manufacturing, commercialization, standardization and FDA regulatory pathway for our devices/tests. These efforts are in conjunction UC Davis start-up company SensIT Ventures.